STOCK TITAN

GSK plc (GSK) reports 4,045,411,246 voting rights as of July 2026

(Neutral)
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

GSK plc reported its share capital and voting rights position as at 31 July 2026 in line with Financial Conduct Authority disclosure requirements.

The company had 4,316,292,310 Ordinary Shares of 31¼ pence each in issue, of which 270,881,064 were held in Treasury. This results in 4,045,411,246 total voting rights, which shareholders may use as the denominator when assessing whether they must notify interests or changes in interests under the Disclosure Guidance and Transparency Rules.

Positive

  • None.

Negative

  • None.
Issued share capital 4,316,292,310 Ordinary Shares Number of Ordinary Shares in issue as at 31 July 2026
Treasury shares 270,881,064 Ordinary Shares Ordinary Shares held in Treasury as at 31 July 2026
Total voting rights 4,045,411,246 Total number of voting rights in the company as at 31 July 2026
Nominal share value 31¼ pence Nominal value per Ordinary Share in issued share capital
total voting rights financial
"the total number of voting rights in the Company is 4,045,411,246"
The total voting rights number is the count of shares that carry the right to vote at a company’s shareholder meetings, reflecting how much voting power exists in the market. Investors use it to understand control and influence—like knowing how many votes are in play when measuring ownership stakes, calculating a shareholder’s voting percentage, or assessing how easy it would be for a holder to sway decisions.
Treasury financial
"of which 270,881,064 Ordinary Shares were held in Treasury"
The treasury is the department or area within a government or organization responsible for managing its money, finances, and financial strategies. It handles tasks like collecting revenue, paying bills, and planning for future financial needs, much like a household manages its budget. For investors, understanding the treasury is important because it influences interest rates, government spending, and overall economic stability.
Disclosure Guidance and Transparency Rules regulatory
"under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules"
Disclosure guidance and transparency rules are the standards and regulations that require companies to share clear, timely information about their finances, risks, operations and material events. They matter to investors because consistent, honest reporting is like a car’s dashboard — it reveals the data you need to judge safety and performance and make informed buying or selling decisions. Strong disclosure reduces surprises and helps keep markets fair and efficient.
Foreign private issuer regulatory
"REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"
A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What total voting rights did GSK (GSK) report as of 31 July 2026?

GSK reported 4,045,411,246 total voting rights as of 31 July 2026. Shareholders may use this figure as the denominator when determining whether they must notify interests or changes under UK Disclosure Guidance and Transparency Rules.

How many shares were in GSK (GSK) issued share capital on 31 July 2026?

On 31 July 2026, GSK’s issued share capital consisted of 4,316,292,310 Ordinary Shares of nominal value 31¼ pence each. This total includes shares held in Treasury, which do not carry voting rights while so held.

How many GSK (GSK) shares were held in Treasury at the July 2026 reference date?

At 31 July 2026, GSK held 270,881,064 Ordinary Shares in Treasury. These Treasury shares are part of issued share capital but are excluded from voting rights, leaving 4,045,411,246 voting rights in the company.

Why is GSK’s (GSK) total voting rights figure important for shareholders?

The total voting rights figure of 4,045,411,246 is used by shareholders as the denominator to calculate ownership percentages. This helps determine whether they must notify interests or changes under the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules.

What regulatory framework governs GSK’s (GSK) voting rights disclosure?

The disclosure is made in conformity with the Financial Conduct Authority’s Disclosure Guidance and Transparency Rule 5.6.1R. This framework sets out when issuers must notify the market about changes in total voting rights and share capital.

What type of shares does GSK (GSK) list in its July 2026 capital structure update?

GSK lists Ordinary Shares of 31¼ pence each in its capital structure update. As at 31 July 2026, there were 4,316,292,310 such shares issued, including 270,881,064 held in Treasury that do not contribute to total voting rights.
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
 
 
For the month of August 2026
 
Commission File Number 001-15170
 
 
GSK plc
(Translation of registrant's name into English)
 
 
79 New Oxford Street, London, WC1A 1DG
(Address of principal executive office)
 
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
 
 
 
 
Issued: 3 August 2026, London UK
 
Total Voting Rights
 
 
 
 
In conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R, GSK plc (the 'Company') hereby notifies the market of the following:
 
The Company's issued share capital as at 31 July 2026 consisted of 4,316,292,310 shares of 31 ¼ pence each ('Ordinary Shares'), of which 270,881,064 Ordinary Shares were held in Treasury.
 
Therefore, the total number of voting rights in the Company is 4,045,411,246. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
 
Notifications may be sent to company.secretary@gsk.com.
 
 
V A Whyte
Company Secretary
 
3 August 2026
 
 
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
 
 
Registered in England & Wales:
No. 3888792
 
 
Registered Office:
79 New Oxford Street
London
WC1A 1DG
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
GSK plc
 
(Registrant)
 
 
Date: August 03, 2026
 
 
 
 
By:/s/ VICTORIA WHYTE
--------------------------
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
behalf of GSK plc